The use of histotripsy as intratumoral immunotherapy beyond tissue ablation—the rationale for exploring the immune effects of histotripsy
Takuya Osada(Rakuten (Japan)), H. Kim Lyerly(Duke University), Howuk Kim(Inha University), Huaiyu Wu(Southeast University), Michael A. Morse(Duke Medical Center), Pei Zhong(Duke University), Joshua C. Snyder(Duke University), Benjamin C. Kreager(North Carolina State University), Jun Ren(Wuhan University), Mengyue Chen(North Carolina State University), Yuhang Zhao(Zhejiang International Studies University), Xiaoning Jiang(North Carolina State University)
Cited by 15
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
|New England Journal of Medicine|2008|1.5k
Advantages and challenges of relaxor-PbTiO3 ferroelectric crystals for electroacoustic transducers – A review
|Progress in Materials Science|2014|847
NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines
|Journal of the National Comprehensive Cancer Network|2007|636